Choosing to participate in an expanded access program is an important personal decision. Talk with your doctor and family members or friends about deciding to join a research study. To learn more about this study, please have your doctor contact the study research staff using the Contacts provided. For general information, see the link provided in More Information.
Lumasiran administered as a subcutaneous (SC) injection
Other Name: ALN-GO1
- Documented diagnosis of Primary Hyperoxaluria Type1
- Meet the urine oxalate excretion requirements
- Clinically significant health concerns (with the exception of PH1)
- An estimated GFR of ≤ 45 mL/min/1.73m2 at screening
- Clinically significant abnormal laboratory results at screening
- Received an investigational agent within 30 days before the first dose of lumasiran or are in follow-up of another clinical study
- Previously or currently participating in lumasiran clinical study
- History of renal or liver transplant
- Women who are pregnant, planning a pregnancy, or breast-feeding or those of child bearing potential and not willing to use contraception
Alnylam EAP Hotline
Tom Brown, PhD
Expanded Access program information for companies listed in the Expanded Access Company Directory is pulled daily from ClinicalTrials.gov, a resource provided by the National Institutes of Health in cooperation with the U.S. Food and Drug Administration. Click here for more information about ClinicalTrials.gov.